Our mechanistic investigations suggest that the enhanced cytotoxic effects of RS5517 against Dox-treated CRC cells can be explained by inhibition of a NHERF1-mediated survival response restricted to cells that silence β-catenin (Fig. 5). This evidence concerns the gene NHERF1 and colorectal carcinoma.